Stay updated on Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page.

Latest updates to the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1 is displayed across the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedGlossary show/hide controls were added and update-related labels were adjusted. Versioning information was updated to Revision: v3.4.0 and the previous Revision: v3.3.4 was removed, along with wording about No FEAR Act data.SummaryDifference0.3%

- Check40 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 on the page. This is a minor front-end version update and does not affect study information or functionality.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page now lists multiple study sites across CT, FL, IL, ME, MA, NC, OH, PA, SC, and TN under the Locations section.SummaryDifference0.9%

- Check77 days agoChange DetectedAdded the principal investigator, Lauren Carcas, MD, and contact email; expanded recruitment sites to Kendall and Plantation, FL (Miami Cancer Institute at Baptist Health), bringing total locations to 14, and updated the Last Update Posted (Estimated) to 2025-12-03.SummaryDifference1%

Stay in the know with updates to Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page.